Alcobra Ltd. Report issue

For profit Phase 3
Founded: Tel Aviv Israel (2008)
Status: Acquired by Arcturus Therapeutics (2017)

Organization Overview

First Clinical Trial
2009
NCT00995085
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

pyridoxine (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Fragile X Syndrome (Phase 2)

Hyperkinesis (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 1